nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Access to information on drug regulation in the countries of Central and Eastern Europe
|
Vrhovać, Boźidar |
|
2013 |
9 |
3 |
p. 173-178 |
artikel |
2 |
Access to regulatory information in Malaysia – a preliminary study
|
Razak, Dzulkifli Abdul |
|
2013 |
9 |
3 |
p. 179-186 |
artikel |
3 |
An ISDB survey to assess the degree of transparency of drug regulatory agencies
|
Bardelay, Danielle |
|
2013 |
9 |
3 |
p. 151-155 |
artikel |
4 |
Author Index Volume 9 (1996)
|
|
|
2013 |
9 |
3 |
p. 219-220 |
artikel |
5 |
Drug regulation and the tradition of secrecy
|
Dukes, M.N. Graham |
|
2013 |
9 |
3 |
p. 143-149 |
artikel |
6 |
Globalisation of drug regulation and drug regulators in developing countriesGroping in the dark even when there is a light switch; an example from Sri Lanka
|
Weerasuriya, K. |
|
2013 |
9 |
3 |
p. 187-193 |
artikel |
7 |
International harmonisation – the need for transparency
|
Hodgkin, Catherine |
|
2013 |
9 |
3 |
p. 195-199 |
artikel |
8 |
Secrecy and medicines
|
Medawar, Charles |
|
2013 |
9 |
3 |
p. 133-141 |
artikel |
9 |
Secrecy in drug regulationLicensing documentation on the Norplant® contraceptive
|
Ollila, Eeva |
|
2013 |
9 |
3 |
p. 161-172 |
artikel |
10 |
Side effects: freedom of information and the communication of doubt
|
Herxheimer, Andrew |
|
2013 |
9 |
3 |
p. 201-210 |
artikel |
11 |
Statement of the International Working Group on transparency and accountability in drug regulation
|
(HAI) Health Action International and the Dag Hammarskjöld Foundation, |
|
2013 |
9 |
3 |
p. 211-217 |
artikel |
12 |
The case of contaminated blood products in Japan
|
Beppu, Hirokuni |
|
2013 |
9 |
3 |
p. 157-159 |
artikel |
13 |
Time to lift the veil of secrecy
|
|
|
2013 |
9 |
3 |
p. 131-132 |
artikel |